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Purpose/Objective: Dysphagia remains a side effect 
influencing quality of life for head and neck cancer (HNC) 
patients after radiotherapy. We evaluated relationship 
between planned dose involvement and acute and late 
dysphagia in HNC patients treated with Intensity Modulated 
Radiation treatments, after a re-contouring of constrictors 
muscles (PCs) and cricopharyngeal muscle (CM). 
Materials and Methods: Between December 2011 and 
December 2013, 56 patients, with histologically proven HNC, 
were treated with IMRT or VMAT. The PCs and CM were re-
contoured. We used recent guidelines to define dose-
constraints of constrictors muscles (PCs) and cricopharyngeal 
muscle (CM). Correlations between acute and late toxicity 
and dosimetric parameters were evaluated. Endpoints were 
analyzed using univariate logistic regression. 
Results: Median follow up was 24 months (range 10-36 
months). An increasing risk to develop acute dysphagia was 
observed when constraints to middle PC are not respected 
(Dmean ≥ 50Gy, Dmax >60Gy, V50 >70% with a p=0.05). 
Superior PC was not correlated with acute toxicity, but only 
with early-late dysphagia (until to 6 months after 
radiotherapy). The inferior PC is not correlated with 
dysphagia; for cricopharyngeal muscle only Dmax > 60Gy is 
correlated with acute dysphagia ≥ G2. No correlations were 
found at 12 months of follow up. Univariate logistic 
regression analysis for clinical parameters showed a 
significant correlation with oropharynx primary site (p-value 
< 0.05) and acute/late disphagia. Late xerostomia ≥ G2 is 
statistically related with late disphagia ≥ G2 (p-value < 0.05). 
Conclusions: Superior PC has a major role, being correlated 
with dysphagia at 3 and 6 months after the treatments; the 
middle PC mantains this correlation only at 3 months from 
beginning of radiotherapy but it does not have influence on 
late dysphagia. Inferior PC and CM have a minimum impact 
on the swallowing symptoms. 
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Purpose/Objective: Previous analyses showed that a larger 
parotid gland (PG) shrinkage and a lower PG Dmean predicted 
a faster recovery from xerostomia (XERO) in a group of 85 
patients (pts) treated in a single institute for oropharingeal 
SCC with IMRT. On the contrary, data on a previously 
analysed subgroup of 25/85 pts, showed a larger PG shrinkage 
to predict a more intensive (severe and persistent) XERO in 
the acute phase. Data were re-analyzed by considering PG 
shrinkage as surrogate of a higher reactivity to RT in terms of 
precocity of XERO and subsequent faster recovery. 
Materials and Methods: All patients included in the study 
were treated with IMRT (+ CHT in 75/85 pts) from 10/2007 to 
06/2010 and underwent to weekly CT scans during treatment. 
PG were contoured on the mid treatment CT scan and the % 
change relative to the planning CT and the weighted average 
shrinkage were calculated for each PG/pt. XERO was defined 
as ≥ grade 2 dry mouth according to CTCAE v3.0 and was 
assessed weekly during IMRT and then at 3, 6, 12 and 24 
months. Large and small PG shrinkage pts were defined 
taking the median shrinkage at mid treatment as a cut-off 
(19.5%). PG shrinkage was found to better discriminate 
between patients with and without acute XERO when 
considering the score at the 3rd week; then, for current 
investigation, XERO at the 3rd week, at 12 and 24 months 
(XERO3w,12m,24m) were considered:. Uni and multi-variable 
logistic models (retaining in the model variables with p-
value<0.20) were assessed considering weighted average PG 
shrinkage, PG mean dose (of each parotid and the weighted 
average WA_Dmean) and selected clinical variables (including 
chemotherapy, age, sex, BMI). 
Results: Regarding XERO3w and XERO24m models including 
WA_Dmean and a large PG shrinkage were the most 
predictive with a moderate discriminative power (AUC: 0.67-
0.72, p<0.04); the impact of large PG shrinkage was inverted 
between the two times, being predictive of an increased risk 
for XERO3w (OR:2.6, 95%CI:1.0-6.7) and protective for 
XERO24m (OR:0.24 95%CI:0.07-0.83). The same two variables 
were considered to predict XERO12m, despite the impact of 
large PG shrinkage was modest (not significant, p=0.30). The 
corresponding two-variable model was moderately predictive 
and of borderline significance (AUC:0.65, p=0.09) and was in 
line with a progressive shift of the two curves (large vs small 
shrinkage) passing from XERO3w to XERO24m (see Figure). 
 
 
Conclusions: For a given WA_Dmean, patients whose PG 
largely shrink during IMRT are less likely to be long-term 
supplemental fluids dependent and, at the same time, have 
an increased risk to experience early XERO. This result 
suggests PG shrinkage as a quantitative score of the 
individual reactivity to IMRT, showing that pts with early 
XERO better recover from the damage. PG shrinkage alone to 
predict XERO may be a confounding factor if not combined 
with the dosimetry information. 
